GGrantIndex
← Leaderboards

Robert L Carithers

University Of Washington

$2,068,652
Attributed
$4,187,713
Total exposure
10
Grants
1
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $641.2K · FY200814
$1M$750K$500K$250K$0
'08
'09
'10
'11
'12
'13
'14

Funding mix

By agency

NIH$4,187,713 · 10

By mechanism

U01$3,178,592 · 1
R01$951,161 · 1
M01$57,960 · 8

Top collaborators

Most similar at University Of Washington

Same institution · by research overlap

Others in their field

Top investigators on “Clinical Research

Research focus

Clinical ResearchHuman SubjectHuman Therapy EvaluationHepatitis CInterferon AlphaMicroorganism Disease ChemotherapyAntiviral AgentsHepatitis C VirusGenotypeDrug Screening /EvaluationHepatitis BClinical TrialsChronic Disease /DisorderPlacebosBiochemicalClinicGeographic LocationsDatabasesComputer SystemsAlaska NativeGrantCombined Modality TherapyEmtricitabineDesign

Grant awards (26)

Hepatitis Beta Research Network Clinical Center in Pacific Northwest/Alaska$294,756
U01 · FY2014 · DK · contact PI
Hepatitis Beta Research Network Clinical Center in Pacific Northwest/Alaska$596,988
U01 · FY2013 · DK · contact PI
Hepatitis Beta Research Network Clinical Center in Pacific Northwest/Alaska$545,775
U01 · FY2012 · DK · contact PI
Hepatitis Beta Research Network Clinical Center in Pacific Northwest/Alaska$437,657
U01 · FY2011 · DK · contact PI
Hepatitis Beta Research Network Clinical Center in Pacific Northwest/Alaska$641,174
U01 · FY2010 · DK · contact PI
Hepatitis Beta Research Network Clinical Center in Pacific Northwest/Alaska$507,735
U01 · FY2009 · DK · contact PI
Hepatitis Beta Research Network Clinical Center in Pacific Northwest/Alaska$154,507
U01 · FY2008 · DK · contact PI
STUDIES OF THE NATURAL HISTORY OF HEPATITIS C IN LIVER$321,052
R01 · FY2002 · DK
STUDIES OF THE NATURAL HISTORY OF HEPATITIS C IN LIVER$312,911
R01 · FY2001 · DK
STUDIES OF THE NATURAL HISTORY OF HEPATITIS C IN LIVER$317,198
R01 · FY2000 · DK
ADEFOVIR FOR HEPATITIS B$3,864
M01 · FY2000 · RR
INTRON A AND 2 DOSES OF RIBAVIRIN$3,864
M01 · FY2000 · RR
CONTINUOUS VS 24 WK COURSES OF INTRON A THERAPY FOR HEPATITIS C VIRUS INFECTION$3,864
M01 · FY2000 · RR
PEG IFN VS. INTRON A FOR CHRONIC HEPATITIS C$3,864
M01 · FY2000 · RR
PEG IFN VS. INTRON A FOR CHRONIC HEPATITIS C$3,864
M01 · FY2000 · RR
INTRON A AND 2 DOSES OF RIBAVIRIN$3,864
M01 · FY2000 · RR
CONTINUOUS VS 24 WK COURSES OF INTRON A THERAPY FOR HEPATITIS C VIRUS INFECTION$3,864
M01 · FY2000 · RR
TRIAL OF URSODEOXYCHOLATE FOR PRIMARY BILIARY CIRRHOSIS$3,864
M01 · FY2000 · RR
INTERFERON THERAPY IN CHRONIC HEPATITIS C$3,864
M01 · FY2000 · RR
INTERFERON THERAPY IN CHRONIC HEPATITIS C$3,864
M01 · FY2000 · RR
INTRON A VS INTRON A + RIBAVIRIN FOR HEPATITIS C IN INTERFERON NAIVE PATIENTS$3,864
M01 · FY2000 · RR
INTRON A VS INTRON A + RIBAVIRIN FOR HEPATITIS C IN INTERFERON NAIVE PATIENTS$3,864
M01 · FY2000 · RR
INTRON A VS INTRON A + RIBAVIRIN FOR TREATMENT OF RELAPSE IN PATIENTS$3,864
M01 · FY2000 · RR
INTRON A VS INTRON A + RIBAVIRIN FOR TREATMENT OF RELAPSE IN PATIENTS$3,864
M01 · FY2000 · RR
ADEFOVIR FOR HEPATITIS B$3,864
M01 · FY2000 · RR
URSODEOXYCHOLATE(UDCA) VS UDCA AND METHOTREXATE$0
M01 · FY2000 · RR